How does Alzheimer’s affect the brain? Here’s a look at what parts of the brain Alzheimer’s affects and how the disease progresses. Lapses in…
TauRx’s Alzheimer’s anti-tau drug, HMTM, appears to slow cognitive decline and reduce brain atrophy. There’s just one problem — and it involves blue pee….
Here’s a closer look at a kind of dementia that often causes loss of speech: Primary progressive aphasia. Shedding further light on the mystery…
Scientists are exploring the role of tau tangles in Alzheimer’s, and whether addressing these misfolded proteins could treat the disease. Here’s what you need…
Neurobiologist Karl Herrup shares his take on why the field of Alzheimer’s has struggled to find a cure, and what it would take to…
While recent work suggests personality traits may be associated with hallmarks of Alzheimer’s pathology, it does not show cause-and-effect or associate these hallmarks with…
In our LiveTalk series, Being Patient spoke with Jason Ulrich, associate professor of neurology at Washington University in St. Louis, about the complex relationship between…
In our LiveTalk series, Being Patient explored the inner workings of the Wisconsin Registry for Alzheimer’s Prevention, a long-running study of people at risk…
What if we think of Alzheimer’s not as one disease, but three separate ones, with overlapping symptoms? Researchers behind a new study say Alzheimer’s…
The CEO of drug company AC Immune shared her thoughts on a recent failed tau vaccine trial, lessons learned, and what comes next. The…
While Biogen’s experimental Alzheimer’s treatment aducanumab faced yet another snag recently in its convoluted path toward FDA approval, other drugs companies are catching up:…
Neurologist Marwan Sabbagh, director of the Cleveland Clinic Lou Ruvo Center for Brain Health, discusses the challenges and breakthroughs in diagnosing Alzheimer’s. How Does…
While some scientists are focused on targeting beta-amyloid plaques to treat Alzheimer’s, others are honing in on another hallmark of the disease — pathological…
An Op-Ed by Benjamin Stecher Benjamin Stecher was diagnosed with Parkinson’s disease at the age of 29. He has since become actively involved in…
Alzheimer’s main hallmarks — beta-amyloid plaques and tau tangles — have long been the focus of the quest to come up with an Alzheimer’s…